Global Bioengineered Protein Drugs Market Size By Disease (Cancer, Diabetes), By Method Of Drug Delivery (Novel approaches, Traditional methods), By Drug Types (Peptide hormones, Recombinant protein drugs), By Technology (Genetic engineering, Pharming), By End-User (CROs, Research institutes), By Geographic Scope And Forecast

Bioengineered Protein Drugs Market Size And Forecast

Bioengineered Protein Drugs Market size was valued at USD 340.1 Billion in 2023 and is projected to reach USD 560.9 Billion by 2030, growing at a CAGR of 8.8% from 2024 to 2030.

The increased incidences of diseases like diabetes, cancer, heart disease, asthma, and others are a major driving force in the Bioengineered Protein Drugs Market. These drugs have very few side effects, which may increase their popularity. Health professionals have already been suggesting these drugs, propelling the overall market for bioengineered protein drugs. Furthermore, the growing importance of preventive care in the healthcare sector improves sales opportunities for bioengineered protein drugs in the formulations of vaccines. The Global Bioengineered Protein Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Bioengineered Protein Drugs Market Definition

Bioengineering is the implementation of engineering techniques and materials in the field of biology. Proteins are polymers of amino acids that play a key role in the body’s function. Genetic engineering is used to create bioengineered proteins. They’re also known as recombinant proteins. Bioengineered protein medications are used to treat human injuries, hormonal disorders, cancers, and chronic diseases like asthma, diabetes, and heart disease, among others.

Proteins are essential for the maintenance of an organism’s structural and functional aspects. A protein molecule is made up of a long chain of amino acids that regulates all biological functions of the body such as DNA replication, metabolic reactions, and other vital expressive functions. Due to their safety, specificity, bioreactivity, and rate of success in curing life-threatening diseases and injuries, these special drugs are gaining traction in the pharmaceutical industry.

Global Bioengineered Protein Drugs Market Overview

The rising prevalence of chronic diseases, combined with the biopharmaceuticals industry’s extensive technological progress, have emerged as key driving forces for the bioengineered protein therapeutics market. The rise in the prevalence of diseases like diabetes, cancer, asthma, heart disease, and others is a major driving force in the Bioengineered Protein Drugs Market. According to WHO, the population having diabetes globally will reach 366 million by 2030, positively influencing the rapid growth of the market.

Bioengineered protein drugs are said to have better PK and PD because they are target specific and highly efficient. Other factors driving the growth of this market include technological advancements in bioengineering drug proteins, targeted drug delivery methods for effective treatment, and rising healthcare expenditure. However, the complications involved in disease treatment with bioengineered protein drugs, as well as the ever-increasing cost of drugs are likely to hinder the growth of the global market during the forecast period.

Also, the high cost of bioengineered protein drugs limits the market’s growth. Furthermore, complications associated with the treatment of certain illnesses with bioengineered drugs impede the global expansion of bioengineered protein drugs. However, recognizing the booming market for bioengineered protein drugs, market participants are increasing their investments in the development of a diverse range of products such as vaccines, therapeutic proteins, and monoclonal antibodies.

Global Bioengineered Protein Drugs MarketSegmentation Analysis

The Global Bioengineered Protein Drugs Market is segmented on the basis of Disease, Method Of Drug Delivery, Drug Types, Technology, End-User, And Geography.

Bioengineered Protein Drugs Market, By Disease

• Cancer
• Diabetes
• Blood disorders
• Skin diseases
• Neurodegenerative diseases
• Heart diseases
• Infectious diseases
• Respiratory diseases
• Autoimmune disorders
• Congenital diseases
• Arthritis
• Others

Based on Disease, The market is segmented into Cancer, Diabetes, Blood disorders, Skin diseases, Neurodegenerative diseases, Heart diseases, Infectious diseases, Respiratory diseases, Autoimmune disorders, Congenital diseases, Arthritis, and Others. Increased incidences of Cancer and Diabetes throughout the globe make cancer and diabetes sub-segment the highest revenue earning segment and is expected to continue growing.

As per the National Health Commission, more than 2,000 people died in China in August 2019 from contagious diseases like plague and cholera. Such a high death rate encourages the use of therapeutics, particularly in highly populated countries like China and India. An increase in the geriatric population also impacts the growth positively for the Arthritis segment growth. Other sectors are also growing due to the factors like lesser side effects, better absorbability, ease of dosing, and many others.

Bioengineered Protein Drugs Market, By Method Of Drug Delivery

• Novel approaches
• Traditional methods

Based on Method Of Drug Delivery, The market is segmented into Novel approaches and Traditional methods. The bioengineered protein drugs industry is bifurcated into novel approaches, and traditional practices on the basis of drug delivery methods. Traditional procedures are used to hold the highest market share. But, in recent times due to heavy R&D investments and shifting toward newer delivery methods, novel technics are getting more boost. A few of the difficulties related to parenteral administration have been addressed by PEGylation and polymeric depot technologies.

Although much investigation has been concentrated on non-invasive paths like peroral, pulmonary, and transdermal for protein and peptide delivery in order to increase patient compliance, their delivery through the use of non-invasive routes remains a challenge due to enzymatic instability and poor absorption. The pulmonary route has had some success, as evidenced by the FDA’s recent approval of inhalable insulin. The development of such an oral dose for protein therapeutics remains the most desirable, but also the most difficult.

Bioengineered Protein Drugs Market, By Drug Types

• Peptide hormones
  1. Insulin
  2. Growth hormones
  3. Luteinizing hormones and follicle stimulating hormones
  4. Erythropoietin
• Recombinant protein drugs
• Vaccines
  1. Live attenuated
  2. Toxoid
  3. Inactivated or killed vaccines
  4. Subunit or conjugate
• Therapeutic enzymes
  1. Digestive
  2. Metabolic
  3. Other enzymes
• Cytokines
  1. Interleukins
  2. Interferons
  3. Colony stimulating factors
• Peptide antibiotics
• Monoclonal antibodies
• Replacement proteins
• Blood products
  1. Antithrombin
  2. Immune globulins
  3. Thrombin
  4. C1 esterase inhibitor
  5. Coagulation factors
  6. Alpha 1-protease inhibitor

Based on Drug Types, The market is segmented into Peptide hormones, Recombinant protein drugs, Vaccines, Therapeutic enzymes, Cytokines, Peptide antibiotics, Monoclonal antibodies, Replacement proteins, and Blood products. The bioengineered protein drugs industry is bifurcated into peptide hormones, recombinant protein drugs, therapeutic enzymes, vaccines, cytokines, peptide antibiotics, replacement proteins, monoclonal antibodies, and blood products on the basis of drug types. Due to its increased use in therapies for cancer, autoimmune diseases, and inflammations, monoclonal antibodies are the most appealing drug type.

Bioengineered Protein Drugs Market, By Technology

• Bioreactors and microbial cell fermentation
• Fractionation
• Genetically modified organisms
• Genetic engineering
• Pharming
• Cell culture
• Others

Based on Technology, The market is segmented into Bioreactors and microbial cell fermentation, Fractionation, Genetically modified organisms, Genetic engineering, Pharming, Cell culture, and Others. The bioengineered protein drugs industry is bifurcated into bioreactors and microbial cell fermentation, genetic engineering, fractionation, GMOs or genetically modified organisms, pharming, cell culture and others on the basis of technology. Technology advancements like GMOs or genetically modified organisms as well as cell cultures are accelerating market growth. Those two markets are having most of the market share.

Bioengineered Protein Drugs Market, By End-User

• CROs
• Research institutes
• Pharmaceutical and biotechnology companies

Based on End-User, The market is segmented into CROs, Research institutes, and Pharmaceutical and biotechnology companies. The Pharmaceutical and biotechnology companies segment is expected to grow highly due to huge R&D investments put in by them. For example, Eli Lilly invested nearly USD 7.03 billion in 2021, while Pfizer spent approximately USD 13.8 billion.

Bioengineered Protein Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, The Global Bioengineered Protein Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America has appeared as the market leader in the field and also is expected to grow rapidly in the future. The rising prevalence of chronic diseases, as well as the emergence of technically sophisticated protein therapeutics, have emerged as important key driving forces for the market in this region.

During the forecast period, Asia Pacific is expected to exceed North America in the worldwide Bioengineered Protein Drugs Market. The increasing prevalence of chronic disorders, the expansion of healthcare facilities in several Asian economies, and massive investments by key market players are driving the growth of the Asia Pacific Bioengineered Protein Drugs Market. Due to the upsurge of biosimilars in this region, Europe is expected to experience slow growth in the market throughout the forecast period.

Key Players

The “Global Bioengineered Protein Drugs Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Baxter Healthcare, Abbott Laboratories, Bayer Healthcare Pharmaceuticals, Amgen, Eli Lilly and Co., Fresenius Kabi USA, GlaxoSmithKline, Johnson & Johnson, Hoffman-la-Roche, and Merck & Co. Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• April 2022 – Satellite Bio debuts a novel approach toward bioengineering tissues. Synthetic biology, regenerative medicine, cell therapy, cell biology, as well as tissue engineering are all areas of expertise for this company.
• January 2022 – Altos Labs was established as a new biotechnology company dedicated to unraveling the complex biology of cellular rejuvenation programming.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.